Form 4 Tracker
Dyne Therapeutics, Inc.
DYN

44 insider filings · Latest: Jun 26, 2026

Common Stock Transactions
Txn DateAcceptedInsiderTypeSharesAvg PriceValueShares OwnedFiling
Apr 28, 2026Apr 28 8:42 PMAtlas Venture Associates XI, LP
Proposed Sale
1,171$18.04$21.1K

View →

Apr 27, 2026Apr 27 10:15 PMJason P RhodesDirector
Sale
173,493$18.15$3.1M1,206,026(I)

View →

Apr 24, 2026Apr 27 10:15 PMJason P RhodesDirector
Sale
137,948$18.48$2.5M1,241,973(I)

View →

Apr 23, 2026Apr 27 10:15 PMJason P RhodesDirector
Sale
73,108$19.19$1.4M1,270,556(I)

View →

Apr 27, 2026Apr 27 8:49 PMAtlas Venture Opportunity Fund II, LP
Proposed Sale
45,709$18.26$834.6K

View →

Apr 27, 2026Apr 27 8:48 PMAtlas Venture Opportunity Fund I, LP
Proposed Sale
35,947$18.26$656.4K

View →

Apr 27, 2026Apr 27 8:48 PMAtlas Venture Fund XI, LP
Proposed Sale
90,943$18.26$1.7M

View →

Apr 27, 2026Apr 27 8:48 PMAtlas Venture Associates XI, LP
Proposed Sale
894$18.26$16.3K

View →

Apr 24, 2026Apr 24 8:47 PMAtlas Venture Opportunity Fund I, LP
Proposed Sale
28,583$18.90$540.2K

View →

Apr 24, 2026Apr 24 8:46 PMAtlas Venture Opportunity Fund II, LP
Proposed Sale
36,345$18.90$686.9K

View →

Apr 24, 2026Apr 24 8:46 PMAtlas Venture Fund XI, LP
Proposed Sale
72,310$18.90$1.4M

View →

Apr 24, 2026Apr 24 8:45 PMAtlas Venture Associates XI, LP
Proposed Sale
710$18.90$13.4K

View →

Apr 23, 2026Apr 23 8:46 PMAtlas Venture Opportunity Fund I, LP
Proposed Sale
15,148$19.67$298.0K

View →

Apr 23, 2026Apr 23 8:45 PMAtlas Venture Opportunity Fund II, LP
Proposed Sale
19,261$19.67$378.9K

View →

Apr 23, 2026Apr 23 8:45 PMAtlas Venture Fund XI, LP
Proposed Sale
38,322$19.67$753.8K

View →

Apr 23, 2026Apr 23 8:45 PMAtlas Venture Associates XI, LP
Proposed Sale
377$19.67$7.4K

View →

Apr 22, 2026Apr 23 8:15 PMDirk KerstenDirector
Sale
2,652$20.00$53.0K4,196,573(I)

View →

Apr 21, 2026Apr 23 8:15 PMDirk KerstenDirector
Sale
8,300$20.01$166.1K4,199,225(I)

View →

Apr 22, 2026Apr 22 10:27 PMJason P RhodesDirector
Sale
287,956$19.68$5.7M1,285,704(I)

View →

Apr 21, 2026Apr 22 10:27 PMJason P RhodesDirector
Sale
274,297$19.52$5.4M1,345,367(I)

View →

Stock Options & Derivatives
Txn DateAcceptedInsiderTypeSharesExercise PriceShares OwnedFiling
Jun 22, 2026Jun 23 8:07 PMBarry E GreeneDirector
Grant/Award
57,463$20.8757,463(D)

View →

Jun 5, 2026Jun 9 9:15 PMEdward HurwitzDirector
Grant/Award
35,152$17.0435,152(D)

View →

Jun 5, 2026Jun 9 9:13 PMDavid Charles LubnerDirector
Grant/Award
35,152$17.0435,152(D)

View →

Jun 5, 2026Jun 9 9:13 PMJason P RhodesDirector
Grant/Award
35,152$17.0435,152(D)

View →

Jun 5, 2026Jun 9 9:12 PMDirk KerstenDirector
Grant/Award
35,152$17.0435,152(D)

View →

Jun 5, 2026Jun 9 9:12 PMCarlo IncertiDirector
Grant/Award
35,152$17.0435,152(D)

View →

Jun 5, 2026Jun 9 9:09 PMCatherine Stehman-BreenDirector
Grant/Award
35,152$17.0435,152(D)

View →

Jun 5, 2026Jun 9 9:06 PMBrian S PosnerDirector
Grant/Award
35,152$17.0435,152(D)

View →

Feb 12, 2026Feb 17 10:11 PMJohn CoxDirector, CEO & President
Grant/Award
285,000$16.00285,000(D)

View →

Feb 12, 2026Feb 17 10:10 PMDouglas KerrChief Medical Officer
Grant/Award
130,000$16.00130,000(D)

View →

Feb 12, 2026Feb 17 10:09 PMJohanna Friedl-NadererChief Commercial Officer
Grant/Award
90,000$16.0090,000(D)

View →

Feb 12, 2026Feb 17 10:08 PMErick LuceraChief Financial Officer
Grant/Award
105,000$16.00105,000(D)

View →